134753-57-4

Basic information

• Product Name: acide 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-tetrahydro-2-oxo-5-phenylfurane-3-carboxylique
• Synonyms: acide 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-tetrahydro-2-oxo-5-phenylfurane-3-carboxylique
• CAS NO: 134753-57-4
• Molecular Weight: 340.419
• Mol File: 134753-57-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: acide 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-tetrahydro-2-oxo-5-phenylfurane-3-carboxylique(CAS DataBase Reference)
• NIST Chemistry Reference: acide 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-tetrahydro-2-oxo-5-phenylfurane-3-carboxylique(134753-57-4)
• EPA Substance Registry System: acide 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-tetrahydro-2-oxo-5-phenylfurane-3-carboxylique(134753-57-4)

Safety Data

• Hazardous Substances Data: 134753-57-4(Hazardous Substances Data)

Upstream product

• 134753-56-3 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-dihydro-5-phenylfuran-2(3H)-one 
• 4861-79-4 magnesium methyl carbonate 

Downstream Products

• 97839-58-2 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-dihydro-3-methylene-5-phenylfuran-2(3H)-one 
• 777821-90-6 5-(tricyclo<3.3.1.1^3,7>dec-1-yl)-dihydro-3-(dimethylaminomethyl)-5-phenylfuran-2(3H)-one 
• 134753-59-6 1-(tricyclo<3.3.1.1^3,7>dec-1-yl)-3-(dimethylaminomethyl)-1-phenylbutane-1,4-diol 

Relevant articles and documents

Synthese et etude pharmacologique de quelques aminolactones et aminotetrahydrofuranes adamantaniques

This paper describes the synthesis of adamantane aminolactones (AdAL 6 and PhAdAL 16) and their tetrahydrofuran analogues (AdAE 9 and PhAdAE 19).Their convulsant activity was studied in mice.It was found to be weaker than that of the aminolactones or aminotetrahydrofurans, which have a phenyl group in place of the adamantane ring.Studies on the antagonism of the convulsant action of these derivatives, by GABAergic or glycinergic agonists appear to show the simultaneous development of dopaminergic, antiGABAergic (for the AdAE and PhAdAE) and antiglycinergic (for theAdAL and PhAdAL) central activities.These properties could be interesting in the treatment of the late stages of the Parkinson's disease.